Skip to main content

Table 6 Clinical characteristics of patients who developed an infection during immunosuppressive treatment

From: Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

 

No. (%)

Clinical characteristics

Infection

n = 29

No infection

n = 50

P

Cancer stagea

  

0.386

 Stage III

4 (14)

12 (24)

 

 Stage IV

24 (86)

37 (76)

 

Malignancy type

  

0.752

 Melanoma

19 (66)

36 (72)

 

 Solid tumor

10 (34)

13 (26)

 

 Hematologic

0 (0)

1 (2)

 

Immune checkpoint inhibitor type

  

0.758

 Anti-CTLA-4

25 (86)

41 (82)

 

 Anti-PD-1/L1

4 (14)

9 (18)

 

Treatment for diarrhea or colitis

  

0.483

 Steroids alone

18 (62)

26 (52)

 

 Steroids + infliximab

11 (38)

24 (48)

 

Mean length of steroid use (days, SD)

80.4 (116)

46.7 (34.5)

0.063

Length of steroid use

  

0.160

 Short duration (≤ 30 days)

8 (28)

22 (44)

 

 Long duration (> 30 days)

21 (72)

28 (56)

 

Diarrhea grade

  

0.353

 Grade 1

3 (10)

10 (20)

 

 Grade 2–4

26 (90)

40 (80)

 

Colitis grade

  

1.000

 Grade 1

11 (38)

19 (38)

 

 Grade 2–3

18 (62)

31 (62)

 
  1. Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein-4; PD-1/L1, Programmed death-1/ligand 1; SD, standard deviation
  2. aStage of cancer was documented in 28 patients with infection and 49 patients with no infection